Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management

Natasha Szuber, Michelle Elliott, Ayalew Tefferi

Research output: Contribution to journalArticle

Abstract

Disease overview: Chronic neutrophilic leukemia (CNL) is a rare, often aggressive myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis, bone marrow granulocyte hyperplasia, and frequent hepatosplenomegaly. The seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) in the majority of patients with CNL in 2013 anchored a new scientific framework, deepening our understanding of its molecular pathogenesis, providing a diagnostic biomarker, and rationalizing the use of pharmacological targeting. Diagnostic criteria: In 2016, the World Health Organization (WHO) included the presence of activating CSF3R mutations as a central diagnostic feature of CNL. Other criteria include leukocytosis of ≥25 × 109/L comprising >80% neutrophils with <10% circulating precursors and rare blasts, and absence of dysplasia or monocytosis, while not fulfilling criteria for other MPN. Disease updates: Increasingly comprehensive genetic profiling of CNL has disclosed a complex genomic landscape and additional prognostically relevant mutational combinations. Though prognostic determination and therapeutic decision-making remain challenging, emerging data on prognostic markers and the use of newer therapeutic agents, such as JAK inhibitors, are helping to define state-of-the-art management in CNL.

Original languageEnglish (US)
Pages (from-to)212-224
Number of pages13
JournalAmerican journal of hematology
Volume95
Issue number2
DOIs
StatePublished - Feb 1 2020

Fingerprint

Leukemia, Neutrophilic, Chronic
Molecular Biology
Colony-Stimulating Factor Receptors
Leukocytosis
Mutation
Therapeutic Uses
Granulocytes
Hyperplasia
Neoplasms
Decision Making
Neutrophils
Biomarkers
Bone Marrow
Pharmacology

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic neutrophilic leukemia : 2020 update on diagnosis, molecular genetics, prognosis, and management. / Szuber, Natasha; Elliott, Michelle; Tefferi, Ayalew.

In: American journal of hematology, Vol. 95, No. 2, 01.02.2020, p. 212-224.

Research output: Contribution to journalArticle

@article{a7872d8b18ba441684f9d5d15dfcb6b1,
title = "Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management",
abstract = "Disease overview: Chronic neutrophilic leukemia (CNL) is a rare, often aggressive myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis, bone marrow granulocyte hyperplasia, and frequent hepatosplenomegaly. The seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) in the majority of patients with CNL in 2013 anchored a new scientific framework, deepening our understanding of its molecular pathogenesis, providing a diagnostic biomarker, and rationalizing the use of pharmacological targeting. Diagnostic criteria: In 2016, the World Health Organization (WHO) included the presence of activating CSF3R mutations as a central diagnostic feature of CNL. Other criteria include leukocytosis of ≥25 × 109/L comprising >80{\%} neutrophils with <10{\%} circulating precursors and rare blasts, and absence of dysplasia or monocytosis, while not fulfilling criteria for other MPN. Disease updates: Increasingly comprehensive genetic profiling of CNL has disclosed a complex genomic landscape and additional prognostically relevant mutational combinations. Though prognostic determination and therapeutic decision-making remain challenging, emerging data on prognostic markers and the use of newer therapeutic agents, such as JAK inhibitors, are helping to define state-of-the-art management in CNL.",
author = "Natasha Szuber and Michelle Elliott and Ayalew Tefferi",
year = "2020",
month = "2",
day = "1",
doi = "10.1002/ajh.25688",
language = "English (US)",
volume = "95",
pages = "212--224",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Chronic neutrophilic leukemia

T2 - 2020 update on diagnosis, molecular genetics, prognosis, and management

AU - Szuber, Natasha

AU - Elliott, Michelle

AU - Tefferi, Ayalew

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Disease overview: Chronic neutrophilic leukemia (CNL) is a rare, often aggressive myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis, bone marrow granulocyte hyperplasia, and frequent hepatosplenomegaly. The seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) in the majority of patients with CNL in 2013 anchored a new scientific framework, deepening our understanding of its molecular pathogenesis, providing a diagnostic biomarker, and rationalizing the use of pharmacological targeting. Diagnostic criteria: In 2016, the World Health Organization (WHO) included the presence of activating CSF3R mutations as a central diagnostic feature of CNL. Other criteria include leukocytosis of ≥25 × 109/L comprising >80% neutrophils with <10% circulating precursors and rare blasts, and absence of dysplasia or monocytosis, while not fulfilling criteria for other MPN. Disease updates: Increasingly comprehensive genetic profiling of CNL has disclosed a complex genomic landscape and additional prognostically relevant mutational combinations. Though prognostic determination and therapeutic decision-making remain challenging, emerging data on prognostic markers and the use of newer therapeutic agents, such as JAK inhibitors, are helping to define state-of-the-art management in CNL.

AB - Disease overview: Chronic neutrophilic leukemia (CNL) is a rare, often aggressive myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis, bone marrow granulocyte hyperplasia, and frequent hepatosplenomegaly. The seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) in the majority of patients with CNL in 2013 anchored a new scientific framework, deepening our understanding of its molecular pathogenesis, providing a diagnostic biomarker, and rationalizing the use of pharmacological targeting. Diagnostic criteria: In 2016, the World Health Organization (WHO) included the presence of activating CSF3R mutations as a central diagnostic feature of CNL. Other criteria include leukocytosis of ≥25 × 109/L comprising >80% neutrophils with <10% circulating precursors and rare blasts, and absence of dysplasia or monocytosis, while not fulfilling criteria for other MPN. Disease updates: Increasingly comprehensive genetic profiling of CNL has disclosed a complex genomic landscape and additional prognostically relevant mutational combinations. Though prognostic determination and therapeutic decision-making remain challenging, emerging data on prognostic markers and the use of newer therapeutic agents, such as JAK inhibitors, are helping to define state-of-the-art management in CNL.

UR - http://www.scopus.com/inward/record.url?scp=85077537778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077537778&partnerID=8YFLogxK

U2 - 10.1002/ajh.25688

DO - 10.1002/ajh.25688

M3 - Article

C2 - 31769070

AN - SCOPUS:85077537778

VL - 95

SP - 212

EP - 224

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -